# OSTX (OS Therapies Incorporated) - SEC EDGAR Financial Statements

> OS Therapies Incorporated reported $8.11M in total assets and a net loss of $43.77M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/OSTX
- Markdown: https://convexityos.com/fundamentals/OSTX.md
- SEC CIK: 0001795091
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:00 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001795091&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$39.77M | Operating profit |
| Net Income | FY 2025 | -$43.77M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.91 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$14.70M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $432K | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Research & Development | $16.36M | $2.84M | $3.22M |
| **Operating Income** | -$28.71M | -$6.81M | -$4.34M |
| **EBITDA** | -$28.34M | -$6.81M | -$4.34M |
| Interest Income | $249 | -- | $2 |
| Interest Expense | -- | $2.05M | $3.45M |
| **Net Income** | -$28.75M | -$8.88M | -$7.79M |
| Basic EPS | -$0.98 | -$1.28 | -$1.46 |
| **Diluted EPS** | -$0.98 | -$1.28 | -$1.46 |
| Basic Shares Outstanding | -- | 12.4M | 5.4M |
| Diluted Shares Outstanding | 29.3M | 7.0M | -- |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $5.97M | $6.07M | $7.35M | $8.80M | $3.76M | $2.50M | $1.31M | $870K |
| **Operating Income** | -$9.03M | -$8.58M | -$10.17M | -$11.99M | -$6.88M | -$4.84M | -$5.00M | -$2.97M |
| **EBITDA** | -$8.91M | -$8.45M | -$10.04M | -$11.86M | -$6.75M | -$4.73M | -$5.00M | -$2.97M |
| Interest Income | $16K | $46 | $45 | $54 | $65 | $64 | $66 | -- |
| Interest Expense | $621K | $5.6K | $75K | -- | -- | -- | -- | $7.6K |
| **Net Income** | -$11.28M | -$8.63M | -$10.40M | -$13.46M | -$6.88M | -$4.54M | -$3.88M | -$2.99M |
| Basic EPS | -$0.23 | -$0.20 | -$0.27 | -- | -$0.22 | -$0.19 | -$0.18 | -- |
| **Diluted EPS** | -$0.23 | -$0.20 | -$0.27 | -- | -$0.22 | -$0.19 | -$0.18 | -- |
| Diluted Shares Outstanding | 48.1M | 43.9M | 38.7M | -- | 32.0M | 25.1M | 21.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $270K | $5.53M | $39K |
| **Cash & Short-Term Investments** | $270K | $5.53M | $39K |
| **Total Current Assets** | $333K | $5.53M | $790K |
| Property, Plant & Equipment, Net | $2.5K | $5.3K | $8.1K |
| Intangible Assets | $6.50M | -- | $8.1K |
| **Total Non-Current Assets** | $6.51M | $5.3K | $8.1K |
| **Total Assets** | $6.84M | $5.54M | $798K |
| Accounts Payable | $9.94M | $1.66M | $2.72M |
| **Total Current Liabilities** | $11.76M | $4.63M | $24.71M |
| **Total Non-Current Liabilities** | $100K | $100K | $100K |
| **Total Liabilities** | $11.86M | $4.73M | $24.81M |
| Common Stock | $37K | $21K | $5.3K |
| Retained Earnings | -$67.19M | -$38.43M | -$29.52M |
| **Total Stockholders' Equity** | -$6.10M | -$3.27M | -$24.02M |
| Total Equity | -$6.10M | -$3.27M | -$24.02M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $432K | $205K | $918K | $270K | -- | $2.80M | $2.97M | $5.53M |
| **Cash & Short-Term Investments** | $432K | $205K | $918K | $270K | -- | $2.80M | $2.97M | $5.53M |
| **Total Current Assets** | $1.98M | $3.64M | $918K | $333K | $2.32M | $3.55M | $4.10M | $5.53M |
| Property, Plant & Equipment, Net | $405 | $1.1K | $1.8K | $2.5K | $3.2K | $3.9K | $4.6K | $5.3K |
| Intangible Assets | $6.13M | $6.26M | $6.38M | $6.50M | $6.86M | $6.86M | -- | -- |
| **Total Non-Current Assets** | $6.13M | $6.26M | $6.38M | $6.51M | $6.63M | $6.76M | $155K | $5.3K |
| **Total Assets** | $8.11M | $9.90M | $7.30M | $6.84M | $8.95M | $10.31M | $4.25M | $5.54M |
| Accounts Payable | -- | -- | -- | $9.94M | $3.37M | $2.70M | $1.62M | $1.66M |
| **Total Current Liabilities** | $23.91M | $20.64M | $16.95M | $11.76M | $4.15M | $3.46M | $3.54M | $4.63M |
| **Total Non-Current Liabilities** | $100K | $100K | $100K | $100K | $100K | $100K | $100K | $100K |
| **Total Liabilities** | $24.01M | $20.74M | $17.05M | $11.86M | $4.25M | $3.56M | $3.64M | $4.73M |
| Common Stock | $47K | $45K | $39K | $37K | $33K | $30K | $21K | $21K |
| Retained Earnings | -$97.49M | -$86.22M | -$77.58M | -$67.19M | -$53.73M | -$46.85M | -$42.31M | -$38.43M |
| **Total Stockholders' Equity** | -$16.97M | -$11.91M | -$10.82M | -$6.10M | $3.64M | $4.94M | -$4.19M | -$3.27M |
| Total Equity | -$16.97M | -$11.91M | -$10.82M | -$6.10M | $3.64M | $4.94M | -$4.19M | -$3.27M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$28.75M | -$8.88M | -$7.79M |
| Depreciation & Amortization | $363K | $2.8K | $4.2K |
| Stock-Based Compensation | $4.27M | $268K | $0 |
| Change in Payables | $8.27M | -$1.05M | $1.35M |
| **Operating Cash Flow** | -$14.24M | -$7.28M | -$3.01M |
| Capital Expenditure | -$466K | -- | -- |
| **Free Cash Flow** | -$14.70M | -- | -- |
| **Investing Cash Flow** | -$466K | -- | $1.1K |
| **Financing Cash Flow** | $9.44M | $12.78M | $2.87M |
| **Net Change in Cash** | -$5.26M | $5.50M | -$132K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$11.28M | -$8.63M | -$10.40M | -$13.46M | -$6.88M | -$4.54M | -$3.88M | -$2.99M |
| Depreciation & Amortization | $125K | $125K | $125K | $125K | $125K | $113K | $695 | $1.4K |
| Stock-Based Compensation | $1.36M | $1.33M | $1.44M | $1.60M | $815K | $905K | $941K | -- |
| Change in Payables | -- | -- | -- | $6.56M | $672K | $1.09M | -$46K | -$110K |
| **Operating Cash Flow** | -$4.65M | -$5.53M | -$4.56M | -$3.73M | -$4.71M | -$2.36M | -$3.44M | -$2.37M |
| Capital Expenditure | -- | -- | -- | $0 | $0 | -$316K | -$150K | -- |
| **Free Cash Flow** | -- | -- | -- | -$3.73M | -$4.71M | -$2.68M | -$3.59M | -- |
| **Investing Cash Flow** | -- | -- | -- | $0 | $0 | -$293K | -$174K | -- |
| Common Stock Issued | -- | -- | -- | -- | $1.05M | -- | -- | -- |
| **Financing Cash Flow** | $4.88M | $4.82M | $5.21M | $2.12M | $3.78M | $2.48M | $1.05M | $6.05M |
| **Net Change in Cash** | $227K | -$713K | $648K | -$1.61M | -$925K | -$169K | -$2.56M | $3.68M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Return on Assets (ROA) | -420.4% | -160.4% | -976.3% |
| Current Ratio | 0.03x | 1.20x | 0.03x |
| Quick Ratio | 0.02x | 1.20x | 0.00x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -- | -- | -- | -502.7% | -288.9% | -- | -- |
| Return on Assets (ROA) | -539.8% | -397.8% | -483.3% | -420.4% | -204.2% | -138.5% | -265.9% | -160.4% |
| Current Ratio | 0.08x | 0.18x | 0.05x | 0.03x | 0.56x | 1.03x | 1.16x | 1.20x |
| Quick Ratio | 0.02x | 0.01x | 0.05x | 0.02x | -- | 0.81x | 0.84x | 1.20x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
